SEC Form 4 · accession 0001209191-15-047165
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Richard Kassberg
Officer — CBO & Senior Vice President
Period of report
May 21, 2015
Accepted (ET)
May 27, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 21, 2015 | A | 4,400 | — | A | 80,206 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $84.89 | May 21, 2015 | A | 26,300 | A | — | May 20, 2025 | Common Stock | 26,300 | 26,300 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the Company's 2014 Incentive Plan that vests with respect to 1/4 of the underlying shares on each anniversary of the grant date such that the Restricted Stock Units are fully vested on the fourth anniversary of the grant date.
- F2Not applicable.
- F3The option shall vest with respect to 1/4th of the underlying shares on the first anniversary of the grant date and then with respect to 1/48th of the underlying shares monthly thereafter.